King's College London

Research portal

Cannabinoids in psychiatry: They are here to stay

Research output: Contribution to journalReview articlepeer-review

Julia Jiyeon Woo, Emma Van Reekum, Sagnik Bhattacharyya, Zainab Samaan

Original languageEnglish
Pages (from-to)311-313
Number of pages3
JournalBritish Journal of Psychiatry
Issue number6
Accepted/In press2022
Published21 Jun 2022

Bibliographical note

Funding Information: S.B.'s research related to cannabinoids has been funded by: the Medical Research Council, UK; the National Institute for Health Research (NIHR), UK; the Wellcome Trust; the European Commission; the Dowager Countess Eleanor Peel Trust; Parkinson's UK; Rosetrees Trust; and Alzheimer's Research UK. S.B. has participated in advisory boards for or received honoraria as a speaker from Reckitt Benckiser, EmpowerPharm/SanteCannabis, and Britannia Pharmaceuticals; and is working in ongoing collaboration with Beckley Canopy Therapeutics/Canopy Growth (investigator-initiated research), wherein they are supplying the study drug for free for charity-funded research (Parkinson's UK and NIHR Guy's and St Thomas' Biomedical Research Centre). Z.S. is a member of the BJPsych editorial board, and did not take part in the review or decision-making process of this paper. Publisher Copyright: Copyright © The Author(s), 2022. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists.

King's Authors


Cannabinoids are commonly perceived by the public as safe and effective for improving mental health, despite limited evidence to support their use. We discuss reasons why cannabinoids may be particularly compelling for our patients and provide strategies for how psychiatrists can counsel and educate patients on the evidence regarding cannabinoids.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454